Clinicopathological and prognostic significance of XPO1 in solid tumors: meta-analysis and TCGA analysis.

IF 3.9 3区医学 Q1 PATHOLOGY

Expert Review of Molecular Diagnostics Pub Date : 2023-07-01 Epub Date: 2023-06-19 DOI:10.1080/14737159.2023.2224505

Yang Tan, Gang Chen, Rong-Quan He, Zhi-Guang Huang, Yi-Wu Dang, Jia-Yuan Luo, Wan-Ying Huang, Su-Ning Huang, Run Liu, Zhen-Bo Feng

{"title":"Clinicopathological and prognostic significance of XPO1 in solid tumors: meta-analysis and TCGA analysis.","authors":"Yang Tan, Gang Chen, Rong-Quan He, Zhi-Guang Huang, Yi-Wu Dang, Jia-Yuan Luo, Wan-Ying Huang, Su-Ning Huang, Run Liu, Zhen-Bo Feng","doi":"10.1080/14737159.2023.2224505","DOIUrl":null,"url":null,"abstract":"Introduction: Exportin 1 (XPO1) is overexpressed in several solid tumors, and is associated with poor prognosis. Here, we aimed to evaluate the implication of XPO1 expression in solid tumors through a meta-analysis.Methods: PubMed, Web of Science, and Embase databases were searched for articles published until February 2023. Statistical data of the patients, odds ratios and hazard ratios (HRs), together with their corresponding 95% confidence intervals (CIs) were pooled to assess clinicopathological features and survival outcomes. Besides, the Cancer Genome Atlas (TCGA) was used to explore the prognostic significance of XPO1 in solid tumors.Results: A total of 22 works, comprising 2595 patients were included in this study. The results suggested that increased XPO1 expression was associated with a higher tumor grade, more lymph node metastasis, advanced tumor stage, and progressively worse total clinical stage. Additionally, high XPO1 expression was associated with worse overall survival (OS) (HR = 1.43, 95% CI = 1.12-1.81, P = 0.004) and shorter progression-free survival (HR = 1.40, 95% CI = 1.07-1.84, P = 0.01). An analysis using the TCGA dataset showed that high XPO1 expression was associated with poor OS and disease-free survival.Conclusions: XPO1 is a promising prognostic biomarker and may constitute a therapeutic target for solid tumors.PROSPERO registration number: CRD42023399159.","PeriodicalId":12113,"journal":{"name":"Expert Review of Molecular Diagnostics","volume":"23 7","pages":"607-618"},"PeriodicalIF":3.9000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Molecular Diagnostics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737159.2023.2224505","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/6/19 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PATHOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Exportin 1 (XPO1) is overexpressed in several solid tumors, and is associated with poor prognosis. Here, we aimed to evaluate the implication of XPO1 expression in solid tumors through a meta-analysis.

Methods: PubMed, Web of Science, and Embase databases were searched for articles published until February 2023. Statistical data of the patients, odds ratios and hazard ratios (HRs), together with their corresponding 95% confidence intervals (CIs) were pooled to assess clinicopathological features and survival outcomes. Besides, the Cancer Genome Atlas (TCGA) was used to explore the prognostic significance of XPO1 in solid tumors.

Results: A total of 22 works, comprising 2595 patients were included in this study. The results suggested that increased XPO1 expression was associated with a higher tumor grade, more lymph node metastasis, advanced tumor stage, and progressively worse total clinical stage. Additionally, high XPO1 expression was associated with worse overall survival (OS) (HR = 1.43, 95% CI = 1.12-1.81, P = 0.004) and shorter progression-free survival (HR = 1.40, 95% CI = 1.07-1.84, P = 0.01). An analysis using the TCGA dataset showed that high XPO1 expression was associated with poor OS and disease-free survival.

Conclusions: XPO1 is a promising prognostic biomarker and may constitute a therapeutic target for solid tumors.PROSPERO registration number: CRD42023399159.

查看原文本刊更多论文

XPO1在实体瘤中的临床病理和预后意义：荟萃分析和TCGA分析。

导言Exportin 1（XPO1）在多种实体瘤中过度表达，并与不良预后相关。在此，我们旨在通过荟萃分析评估 XPO1 表达在实体瘤中的影响：方法：检索PubMed、Web of Science和Embase数据库中截至2023年2月发表的文章。汇总患者的统计数据、几率比、危险比（HRs）及其相应的95%置信区间（CIs），以评估临床病理特征和生存结果。此外，研究人员还利用癌症基因组图谱（TCGA）来探讨XPO1在实体瘤中的预后意义：本研究共纳入了22项研究，2595名患者。结果表明，XPO1表达增加与肿瘤分级较高、淋巴结转移较多、肿瘤分期较晚以及总临床分期逐渐恶化有关。此外，XPO1的高表达与较差的总生存期（OS）（HR = 1.43，95% CI = 1.12-1.81，P = 0.004）和较短的无进展生存期（HR = 1.40，95% CI = 1.07-1.84，P = 0.01）相关。利用TCGA数据集进行的分析表明，XPO1的高表达与较差的OS和无病生存期相关：XPO1是一种很有前景的预后生物标志物，可能成为实体瘤的治疗靶点：CRD42023399159。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Molecular Diagnostics 医学-病理学

CiteScore

6.60

自引率

0.00%

发文量

审稿时长

1 months

期刊介绍： Expert Review of Molecular Diagnostics (ISSN 1473-7159) publishes expert reviews of the latest advancements in the field of molecular diagnostics including the detection and monitoring of the molecular causes of disease that are being translated into groundbreaking diagnostic and prognostic technologies to be used in the clinical diagnostic setting. Each issue of Expert Review of Molecular Diagnostics contains leading reviews on current and emerging topics relating to molecular diagnostics, subject to a rigorous peer review process; editorials discussing contentious issues in the field; diagnostic profiles featuring independent, expert evaluations of diagnostic tests; meeting reports of recent molecular diagnostics conferences and key paper evaluations featuring assessments of significant, recently published articles from specialists in molecular diagnostic therapy. Expert Review of Molecular Diagnostics provides the forum for reporting the critical advances being made in this ever-expanding field, as well as the major challenges ahead in their clinical implementation. The journal delivers this information in concise, at-a-glance article formats: invaluable to a time-constrained community.